(E)-3-(4-(trifluoromethoxy)phenyl)prop-2-en-1-ol | 866207-70-7

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂醇
• 英文名称: (E)-3-(4-(trifluoromethoxy)phenyl)prop-2-en-1-ol
• 英文别名: 3-(4-Trifluoromethoxyphenyl)prop-2-en-1-ol；(E)-3-[4-(trifluoromethoxy)phenyl]prop-2-en-1-ol
• CAS: 866207-70-7
• 化学式: C₁₀H₉F₃O₂
• 分子量: 218.175
• InChiKey: AQJMZIMWXVFCCI-OWOJBTEDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (E)-3-(4-(trifluoromethoxy)phenyl)prop-2-en-1-ol 在 吡啶 、 titanium(IV) isopropylate 、 叔丁基过氧化氢 、 4-二甲氨基吡啶 、 sodium azide 、 D-(-)-酒石酸二异丙酯 、 氯化铵 作用下， 以 甲醇 、 癸烷 、 二氯甲烷 、 水 为溶剂， 反应 41.0h， 生成 (2S,3S)-3-azido-2-((methylsulfonyl)oxy)-3-(4-(trifluoromethoxy)phenyl)propyl pivalate
  参考文献：
  名称：

  Discovery of Orally Active Hydroxyethylamine Based SPPL2a Inhibitors

  摘要：

  SPPL2a (Signal Peptide Peptidase Like 2a) is an intramembrane aspartyl protease engaged in the function of B-cells and dendritic cells. Despite being an attractive target for modulation of the immune system, selective SPPL2a inhibitors are barely described in the literature. Recently, we have disclosed a selective, small molecular weight agent SPL-707 which confirmed that pharmacological inhibition of SPPL2a leads to the accumulation of its substrate CD74/p8 and as a consequence to a reduction in the number of B-cells as well as myeloid dendritic cells in mice. In this paper we describe the discovery of novel hydroxyethylamine based SPPL2a inhibitors. Starting from a rather lipophilic screening hit, several iterative optimization cycles allowed for its transformation into a highly potent and selective compound 15 (SPL-410) which inhibited in vivo CD74/p8 fragment processing in mice at 10 mg/kg oral dose.

  DOI：

  10.1021/acsmedchemlett.9b00044
• 作为产物：
  描述：

  对三氟甲氧基苯甲醛 在 sodium hydride 、 二异丁基氢化铝 作用下， 以 乙二醇二甲醚 、 甲苯 为溶剂， 反应 0.83h， 生成 (E)-3-(4-(trifluoromethoxy)phenyl)prop-2-en-1-ol
  参考文献：
  名称：

  Synthesis and Antifungal Activities of R-102557 and Related Dioxane-Triazole Derivatives.

  摘要：

  具有二噁烷环的新型三唑化合物被合成。在酸性条件下，二醇前体10与各种芳香醛11-13缩合，得到了一系列二噁烷-三唑化合物14-16。这些化合物14-16的抗真菌活性通过在小鼠感染模型中对白色念珠菌和曲霉菌的评估进行了体内评价。含有单个或两个双键且侧链上带有吸电子基团的芳环衍生物表现出较高的活性。在这些衍生物中，R-102557（16R：Ar=4-（2,2,3,3-四氟丙氧基）苯基）对白色念珠菌、曲霉菌和隐球菌属表现出极佳的体内活性。在大鼠的初步毒性研究中也显示出高度耐受性。

  DOI：

  10.1248/cpb.48.694

文献信息

• Synthesis and Antifungal Activities of R-102557 and Related Dioxane-Triazole Derivatives.
  作者：Sadao OIDA、Yawara TAJIMA、Toshiyuki KONOSU、Yoshie NAKAMURA、Atsushi SOMADA、Teruo TANAKA、Shinobu HABUKI、Tamako HARASAKI、Yasuki KAMAI、Takashi FUKUOKA、Satoshi OHYA、Hiroshi YASUDA

  DOI：10.1248/cpb.48.694

  日期：——

  Novel triazole compounds with a dioxane ring were synthesized. Condensation of the diol precursor 10 with various aromatic aldehydes 11-13 under acidic conditions afforded a series of dioxane-triazole compounds 14-16. The antifungal activities of the compounds 14-16 were evaluated in vivo in mice infection models against Candida and Aspergillus species. High activities were seen for the derivatives with one or two double bond(s) and an aromatic ring substituted with an electron-withdrawing group in th side chain. Among the derivatives, R-102557 (16R : Ar=4-(2, 2, 3, 3)-tetrafluoropropoxy)phenyl)showed excellent in vivo activities against Candida, As-pergillus and Cryptococcus species. It also showed high tolerance in a preliminary toxicity study in rats.

  具有二噁烷环的新型三唑化合物被合成。在酸性条件下，二醇前体10与各种芳香醛11-13缩合，得到了一系列二噁烷-三唑化合物14-16。这些化合物14-16的抗真菌活性通过在小鼠感染模型中对白色念珠菌和曲霉菌的评估进行了体内评价。含有单个或两个双键且侧链上带有吸电子基团的芳环衍生物表现出较高的活性。在这些衍生物中，R-102557（16R：Ar=4-（2,2,3,3-四氟丙氧基）苯基）对白色念珠菌、曲霉菌和隐球菌属表现出极佳的体内活性。在大鼠的初步毒性研究中也显示出高度耐受性。
• Nickel-Catalyzed Alkylation or Reduction of Allylic Alcohols with Alkyl Grignard Reagents
  作者：Bo Yang、Zhong-Xia Wang

  DOI：10.1021/acs.joc.0c00008

  日期：2020.4.3

  selective alkylation and reduction of allylic alcohols with alkyl Grignard reagents were performed. The reaction using Ni(dppe)Cl2 as the catalyst resulted in the cross-coupling of allylic alcohols with primary alkyl Grignard reagents and cyclopropylmagnesium bromide. The reaction catalyzed by the combination of Ni(PCy3)2Cl2 and dcype led to the reduction of allylic alcohols. Secondary alkyl Grignard

  通过选择不同的膦配体，进行了镍催化的选择性烷基化反应和用烷基格氏试剂还原烯丙基醇。使用Ni（dppe）Cl 2作为催化剂的反应导致烯丙基醇与伯烷基格氏试剂和环丙基溴化镁的交叉偶联。Ni（PCy 3）2 Cl 2和dcype的组合催化的反应导致烯丙基醇的还原。除环丙基溴化镁外，仲烷基格氏试剂总是使用Ni（dppe）Cl 2或Ni（PCy 3）2 Cl 2导致烯丙基醇的还原/ dcype作为催化剂。在还原反应中，需要含β-H的烷基格氏试剂。
• Phenylaminopropanol derivatives and methods of their use
  申请人：Kim Younghee Callain

  公开号：US20050222148A1

  公开（公告）日：2005-10-06

  The present invention is directed to phenylaminopropanol derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

  本发明涉及式I的苯胺丙醇衍生物： 或其药学上可接受的盐，含有这些衍生物的组合物，以及它们用于通过单胺再摄取改善的症状的预防和治疗方法，包括但不限于血管运动症状（VMS）、性功能障碍、胃肠道和泌尿系统疾病、慢性疲劳综合征、纤维肌痛综合征、神经系统疾病，以及其中的组合，特别是从包括重性抑郁障碍、血管运动症状、压力性和切勿性尿失禁、纤维肌痛、疼痛、糖尿病性神经病变以及其中的组合的一组中选择的那些症状。
• Dehydrative Allylation between Aldehydes and Allylic Alcohols through Synergistic N‐Heterocyclic Carbene/Palladium Catalysis
  作者：Hiroki Haruki、Shigeo Yasuda、Kazunori Nagao、Hirohisa Ohmiya

  DOI：10.1002/chem.201805955

  日期：2019.1.14

  Dehydrative allylation between widely available aldehydes and allylic alcohols to afford β,γ‐unsaturated ketones was enabled by a synergistic merger of a thiazolium N‐heterocyclic carbene catalyst and a palladium‐bisphosphine catalyst.

  噻唑鎓N-杂环卡宾催化剂和钯-双膦催化剂的协同合并作用使广泛可用的醛与烯丙醇之间的脱水烯丙基化反应生成β，γ-不饱和酮。
• [EN] FUROXANS AS THERAPIES FOR NEURODEGENERATIVE DISORDERS<br/>[FR] FUROXANES UTILISÉS EN TANT QUE THÉRAPIES POUR DES TROUBLES NEURODÉGÉNÉRATIFS
  申请人：UNIV TOLEDO

  公开号：WO2018093762A1

  公开（公告）日：2018-05-24

  Furoxan compounds, compositions comprising the same, and methods of making and using the same, are described.

  Furoxan化合物、包含该化合物的组合物以及制备和使用该化合物的方法被描述。